Meridian Bioscience Stock Hits New 52-Week Low (VIVO)

NEW YORK ( TheStreet) -- Meridian Bioscience (Nasdaq: VIVO) hit a new 52-week low Monday as it is currently trading at $15.48, below its previous 52-week low of $15.71 with 2,352 shares traded as of 9:30 a.m. ET. Average volume has been 342,100 shares over the past 30 days.

Meridian Bioscience has a market cap of $666.3 million and is part of the health care sector and drugs industry. Shares are down 32% year to date as of the close of trading on Friday.

Meridian Bioscience, Inc. operates as an integrated life science company. The company primarily engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. The company has a P/E ratio of 26.2, above the average drugs industry P/E ratio of 25.8 and above the S&P 500 P/E ratio of 17.7.
  • Practice your VIVO trading strategies and win cash in our stock game.

TheStreet Ratings rates Meridian Bioscience as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, premium valuation and weak operating cash flow. You can view the full Meridian Bioscience Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

null

More from Markets

Dow Tumbles as Trump Calls Off North Korea Summit

Dow Tumbles as Trump Calls Off North Korea Summit

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Stocks Could Easily Crater Into Memorial Day Weekend

Stocks Could Easily Crater Into Memorial Day Weekend

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Celgene Shares Rise on Plans to Increase Stock Buybacks

Celgene Shares Rise on Plans to Increase Stock Buybacks